Slide 1: Alkermes 2024: Profitable, Pure-play Neuroscience Company
Alkermes 2024: Profitable, Pure-play Neuroscience Company December 2024 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations with respect t
Slide 3: Alkermes 2024: Profitable, Pure-play Neuroscience Company
Alkermes 2024: Profitable, Pure-play Neuroscience Company >$1B commercial business driven primarily by 4 core products* Proven development capabilities with advancing neuroscience pipeline Positioned for sustained profitability and significant cash generation *Based on revenues from VIVITROL®, ARIST
Slide 4: 2024 Strategic Priorities
2024 Strategic Priorities Driven by 4 core products and streamlined operating structure Initiate phase 2 program Advance internal development candidates and explore external pipeline opportunities Deliver strong commercial growth and profitability Advance orexin 2 receptor agonist program Expand neu
Slide 5: >$1B Commercial Business Primarily Driven by Core Products
>$1B Commercial Business Primarily Driven by 4 Core Products
Slide 6: Topline Growth and Diversification Reflect Evolving Business
Topline Growth and Diversification Reflect Evolving Business *Inclusive of ARISTADA INITIO® **Licensed product (royalty & manufacturing revenue) R12M: Rolling 12 Months Key Product Revenues ($M) $574 $715 $893 $1,049 $1,151
Slide 7: LYBALVI: Oral Treatment Option for Schizophrenia and Bipolar I Disorder
LYBALVI®: Oral Treatment Option for Schizophrenia and Bipolar I Disorder Once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity Indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acu
Slide 8: LYBALVI Launch Growth Trends
LYBALVI® Launch Growth Trends *Source: IQVIA NPA Weekly Post-Launch Weekly TRx* (Through 11/15/2024) Week LYBALVI Quarterly Net Sales ($M)
Slide 9: ARISTADA: LAI for the Treatment of Schizophrenia With Dosing Flexibility
ARISTADA®: LAI for the Treatment of Schizophrenia With Dosing Flexibility *ARISTADA INITIO + single 30 mg oral dose of aripiprazole replaces need for concomitant three weeks of oral aripiprazole for initiation of ARISTADA. The first ARISTADA dose may be administered on the same day as ARISTADA INITI
Slide 10: VIVITROL: LAI for the Treatment of Alcohol Dependence and Opioid Dependence
VIVITROL®: LAI for the Treatment of Alcohol Dependence and Opioid Dependence VIVITROL Annual Net Sales ($M) Extended-release opioid antagonist provides therapeutic levels of naltrexone for a one-month period Indicated for the treatment of alcohol dependence (AD) in patients able to abstain from alco
Slide 11: VUMERITY Offers Long-Term Revenue Growth Opportunity
VUMERITY® Offers Long-Term Revenue Growth Opportunity VUMERITY Royalty & Manufacturing Revenue ($M) $23 $87 $115 $129 Novel oral fumarate for the treatment of relapsing forms of multiple sclerosis (MS) Biogen holds exclusive, worldwide license to commercialize 15% royalty to Alkermes on worldwide ne
Slide 12: Proven Drug Development Capabilities with Advancing Neuroscience Pipeline
Proven Drug Development Capabilities with Advancing Neuroscience Pipeline
Slide 13: Common Symptoms in Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia
Common Symptoms in Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia Symptoms NT1 NT2 IH Excessive daytime sleepiness (EDS) Sleep-onset REM periods (SOREMP) Cataplexy Disrupted nighttime sleep Needed naps: short, refreshing Sleep-related hallucinations Sleep paralysis Brain fog Long sl
Slide 14: Narcolepsy and Idiopathic Hypersomnia in the U.S.
Narcolepsy and Idiopathic Hypersomnia in the U.S. Narcolepsy prevalence 200,000a 100,000 diagnosedb Idiopathic Hypersomnia 40,000 diagnosedc aNarcolepsy Network Fast Facts bCohen et al., Sleep Med 43:14 (2018) and Longstreth et al., Sleep Med 10:422 (2009) prevalence rates applied to U.S. population
Slide 15: ALKS 2680: Investigational Oral Orexin Receptor Agonist
ALKS 2680: Investigational Oral Orexin 2 Receptor Agonist for the Treatment of Narcolepsy and Idiopathic Hypersomnia ALKS 2680 is a highly potent, selective OX2R agonist ≥10-fold more potent than orexin Aa >5,000-fold selectivity relative to OX1Ra ALKS 2680 phase 1 data demonstrated desired pharmace
Slide 16: ALKS 2680 Phase 1b: Randomized, Double-Blind, PBO-Controlled Study
ALKS 2680 Phase 1b: Randomized, Double-Blind, PBO-Controlled Study in Patients With NT1, NT2 and IH Provides Proof-of-Concept Patients had a confirmed diagnosis with no baseline criteria for MWT Key objectives: Safety and tolerability Mean sleep latency on Maintenance of Wakefulness Test (MWT) at ba
Slide 17: ALKS 2680 Phase 1b: Generally Well-Tolerated at all Doses Tested
ALKS 2680 Phase 1b: Generally Well-Tolerated at all Doses Tested in NT1, NT2 and IH Most TEAEs were mild in severity and transient No deaths, serious TEAEs, severe TEAEs, or TEAEs leading to discontinuation Treatment-related TEAEs* reported in >1 subject in each population listed below: NT1: insomn
Slide 18: ALKS 2680 Phase 1b: Dose-Dependent Effect on Wakefulness
Absolute Mean Sleep Latency on Maintenance of Wakefulness Test (MWT) - Mean SE ALKS 2680 Phase 1b: Demonstrated Meaningful, Consistent and Dose-Dependent Effect on Wakefulness in NT1, NT2 & IH Patients Minutes Narcolepsy Type 1 (n = 10) 40 Narcolepsy Type 2 (n = 9) Idiopathic Hypersomnia (n = 8) L
Slide 19: ALKS 2680 Phase 2 Clinical Program Evaluating Once-Daily Administration
ALKS 2680 Phase 2 Clinical Program Evaluating Once-Daily Administration Across a Range of Patient Populations Study n ALKS 2680 Doses Screening Period Double-blind Treatment Period Open-label Extension Period Follow-up Period Primary Endpoint Initial Washout Narcolepsy Type 1 VIBRANCE-1 80 4, 6 & 8
Slide 20: Orexin Receptor Agonist Pathway May Have Potential Applicability in Broad Range of Indications
Orexin 2 Receptor Agonist Pathway May Have Potential Applicability in Broad Range of Indications Select disease states which intersect across aspects of wakefulness, fatigue, mood and cognition Neurology Attention-deficit/hyperactivity disorder Multiple sclerosis fatigue Parkinson’s disease Psychiat
Slide 21: Advancing Multiple Orexin Development Candidates
Advancing Multiple Orexin Development Candidates for Treatment of Neurology & Psychiatry Disorders Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Planned Milestone ALKS 2680 Narcolepsy Type 1 Phase 2 data H2 2025 Phase 2 Data Narcolepsy Type 2 Phase 2 data H2 2025 Idiopathic Hypersomnia Phase 2
Slide 22: Positioned for Robust Profitability and Significant Cash Generation
Positioned for Robust Profitability and Significant Cash Generation
Slide 23: Commercial Performance and Efficient Cost Structure Expected to Drive Meaningful Profitability
Commercial Performance and Efficient Cost Structure Expected to Drive Meaningful Profitability >$1B commercial business driven primarily by 4 core products* Positioned for sustained profitability and significant cash generation Ended 2023 with $813M in cash and investments *Based on revenues from VI
Slide 24: Capital Allocation Strategy
Capital Allocation Strategy Maximize the potential of proprietary commercial products with primary focus on LYBALVI® Pursue external opportunities to expand portfolio with assets that are a strong strategic fit Invest in internal development pipeline to advance new neuroscience candidates Return exc
Slide 25: 2024 Strategic Priorities
2024 Strategic Priorities Driven by 4 core products and streamlined operating structure Initiate phase 2 program Advance internal development candidates and explore external pipeline opportunities Deliver strong commercial growth and profitability Advance orexin 2 receptor agonist program Expand neu
Slide 26: www.alkermes.com © 2024 Alkermes. All rights reserved.
www.alkermes.com © 2024 Alkermes. All rights reserved.